Effects of Peroxisome Proliferator-Activated Receptor-Gamma Activation With Pioglitazone on Plasma Adipokines in Nondiabetic Patients With Either Hypercholesterolemia or Hypertension

American Journal of Cardiology

Volumn 101, Issue 7, 2008, Pages 980-985

  Barac, Ana ^a   Campia, Umberto ^a   Matuskey, Linda A ^a   Lu, Li ^a   Panza, Julio A ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RESISTIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT DURATION;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; LEPTIN; MALE; MIDDLE AGED; PPAR GAMMA; RESISTIN; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 40949146982     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.058     Document Type: Article

References (29)

1. Matsuzawa Y. Adipocytokines: emerging therapeutic targets. Curr Atheroscler Rep 7 (2005) 58-62
2. Campia U., Matuskey L.A., and Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113 (2006) 867-875
3. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., and Quon M.J. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
5. Panza J.A., Garcia C.E., Kilcoyne C.M., Quyyumi A.A., and Cannon III R.O. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91 (1995) 1732-1738
6. Casino P.R., Kilcoyne C.M., Quyyumi A.A., Hoeg J.M., and Panza J.A. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 88 (1993) 2541-2547
7. Kiowski W., Linder L., Kleinbloesem C., van Brummelen P., and Buhler F.R. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation 85 (1992) 1-8
8. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
9. Bohme E., Graf H., and Schultz G. Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets. Adv Cyclic Nucleotide Res 9 (1978) 131-143
10. Han S.H., Quon M.J., Kim J.A., and Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 49 (2007) 531-538
11. Salmenniemi U., Ruotsalainen E., Pihlajamaki J., Vauhkonen I., Kainulainen S., Punnonen K., Vanninen E., and Laakso M. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
12. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., Arita Y., Okamoto Y., Shimomura I., Hiraoka H., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
13. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., Fu Y., Motone M., Yamamoto K., Matsuo A., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
14. Kim H.J., Kang E.S., Kim D.J., Kim S.H., Ahn C.W., Cha B.S., Nam M., Chung C.H., Lee K.W., Nam C.M., and Lee H.C. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66 (2007) 282-289
15. Samaha F.F., Szapary P.O., Iqbal N., Williams M.M., Bloedon L.T., Kochar A., Wolfe M.L., and Rader D.J. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 624-630
16. Majuri A., Santaniemi M., Rautio K., Kunnari A., Vartiainen J., Ruokonen A., Kesaniemi Y.A., Tapanainen J.S., Ukkola O., and Morin-Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 156 (2007) 263-269
17. Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., and Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 290 suppl (2006) E42-E46
18. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
19. Kusminski C.M., McTernan P.G., and Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci (Lond) 109 (2005) 243-256
20. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
21. Reilly M.P., Lehrke M., Wolfe M.I., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
22. Kunnari A., Ukkola O., Paivansalo M., and Kesaniemi Y.A. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 91 (2006) 2755-2760
23. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., and DeFronzo R.A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 4312-4319
24. Szapary P.O., Bloedon L.T., Samaha F.F., Duffy D., Wolfe M.L., Soffer D., Reilly M.P., Chittams J., and Rader D.J. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 182-188
25. Williams L.B., Fawcett R.L., Waechter A.S., Zhang P., Kogon B.E., Jones R., Inman M., Huse J., and Considine R.V. Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab 85 (2000) 2678-2684
26. Nishio K., Sakurai M., Kusuyama T., Shigemitsu M., Fukui T., Kawamura K., Itoh S., Konno N., and Katagiri T. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 29 (2006) 101-106
27. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 (2006) 860-867
28. Ingelsson E., Pencina M.J., Tofler G.H., Benjamin E.J., Lanier K.J., Jacques P.F., Fox C.S., Meigs J.B., Levy D., Larson M.G., et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116 (2007) 984-992
29. Hoo R.L., Chow W.S., Yau M.H., Xu A., Tso A.W., Tse H.F., Fong C.H., Tam S., Chan L., and Lam K.S. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler Thromb Vasc Biol 27 (2007) 2777-2782